title: Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus.
abstract: Tyrosine kinase inhibitors (TKIs) have been shown to affect glucose metabolism in patients with chronic myeloid leukemia (CML); however, their precise mechanism of action remains unknown. We herein report the case of a 57-year-old diabetic CML patient who was resistant to imatinib and initially required 20 units of insulin daily to control his blood glucose levels. After the initiation of dasatinib, the patient's insulin requirements declined rapidly and insulin treatment was discontinued within two weeks. Meanwhile, the fasting C-peptide immunoreactivity increased two-fold, suggesting that dasatinib facilitated the recovery of insulin production. Dasatinib may therefore be beneficial for diabetic CML patients, especially those who require insulin treatment.
authors.affiliation: Department of Metabolism and Endocrinology, Kumamoto Shinto General Hospital (formerly NTT West Kyushu Hospital), Japan. k-ono@shinto-general.jp
authors.forename: Keiko
authors.initials: K
authors.lastname: Ono
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Suzushima
authors.forename: Yuko
authors.initials: Y
authors.lastname: Watanabe
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Kikukawa
authors.forename: Taizou
authors.initials: T
authors.lastname: Shimomura
authors.forename: Noboru
authors.initials: N
authors.lastname: Furukawa
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Kawaguchi
authors.forename: Eiichi
authors.initials: E
authors.lastname: Araki
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D001786:Blood Glucose / Q000378:metabolism; D000069439:Dasatinib; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D006943:Hyperglycemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology*; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D000068877:Imatinib Mesylate; D007328:Insulin / Q000008:administration & dosage / Q000097:blood; D015465:Leukemia, Myeloid, Accelerated Phase / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D000069439:Dasatinib